The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long‐term follow‐up

The routine assessment of progesterone receptor (PR) expression in breast cancer (BC) remains controversial. This study aimed to evaluate the role of PR expression in luminal BC, with emphasis on the definition of positivity and its prognostic significance as compared to Ki67 expression.

[1]  A. Green,et al.  Ki67 assessment in invasive luminal breast cancer: a comparative study between different scoring methods , 2022, Histopathology.

[2]  A. Bild,et al.  ENDORSE: a prognostic model for endocrine therapy in estrogen‐receptor‐positive breast cancers , 2022, Molecular systems biology.

[3]  B. Daniele,et al.  Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis , 2022, Frontiers in Oncology.

[4]  Xiaoyun Mao,et al.  The Role of Progesterone Receptors in Breast Cancer , 2022, Drug design, development and therapy.

[5]  E. Rakha,et al.  Assessment of proliferation in breast cancer: cell cycle or mitosis? An observational study , 2021, Histopathology.

[6]  M. Kerin,et al.  The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer , 2021, BJS open.

[7]  M. Ellis,et al.  Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group , 2020, Journal of the National Cancer Institute.

[8]  V. Ostapenko,et al.  Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma , 2020, Frontiers in Oncology.

[9]  E. Scarpi,et al.  The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial , 2020, Therapeutic advances in medical oncology.

[10]  C. Perou,et al.  Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  W. Han,et al.  Ki-67 Expression is a Significant Prognostic Factor Only When Progesterone Receptor Expression is Low in Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer , 2019, Journal of oncology.

[12]  A. Asif,et al.  The Effect of the New Eighth Edition Breast Cancer Staging System on 100 Consecutive Patients , 2019, Journal of clinical medicine research.

[13]  E. van Limbergen,et al.  Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. , 2018, The oncologist.

[14]  H. Sasano,et al.  Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer. , 2018, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[15]  N. Yao,et al.  Prognostic Impact of Progesterone Receptor Status in Chinese Estrogen Receptor Positive Invasive Breast Cancer Patients , 2017, Journal of breast cancer.

[16]  M. Scognamiglio,et al.  Long-term outcome of breast cancer patients with pathologic N3a lymph node stage. , 2017, Breast.

[17]  I. Ellis,et al.  Further evidence to support bimodality of oestrogen receptor expression in breast cancer , 2017, Histopathology.

[18]  G. S. Hong,et al.  Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer. , 2017, Singapore medical journal.

[19]  Caroline H. Diep,et al.  Progesterone induces progesterone receptor gene (PGR) expression via rapid activation of protein kinase pathways required for cooperative estrogen receptor alpha (ER) and progesterone receptor (PR) genomic action at ER/PR target genes , 2016, Steroids.

[20]  Zhonghu Bai,et al.  Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes , 2016, Journal of Cancer.

[21]  A. Luini,et al.  Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes , 2014, Breast Cancer Research.

[22]  G. Rajan,et al.  Estrogen and progesterone receptor status in breast cancer: a cross-sectional study of 450 women in Kerala, South India , 2014, World Journal of Surgical Oncology.

[23]  A. Goldhirsch,et al.  High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. , 2014, Breast.

[24]  A. Thompson,et al.  Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study , 2013, British Journal of Cancer.

[25]  Andrew H. Beck,et al.  Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype , 2013, Breast Cancer Research.

[26]  C. Perou,et al.  Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  H. Putter,et al.  Competing risks in epidemiology: possibilities and pitfalls. , 2012, International journal of epidemiology.

[28]  G. Hortobagyi,et al.  Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers , 2012, Cancer.

[29]  A. Baghestani,et al.  How to control confounding effects by statistical analysis , 2012, Gastroenterology and hepatology from bed to bench.

[30]  Early Breast Cancer Trialists' Collaborative Group.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[31]  D. Allred.  Issues and updates: evaluating estrogen receptor-α, progesterone receptor, and HER2 in breast cancer , 2010, Modern Pathology.

[32]  M. Piccart-Gebhart,et al.  Value of Ki67 in breast cancer: the debate is still open. , 2010, The Lancet. Oncology.

[33]  M. Dowsett,et al.  Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[35]  Adrian V. Lee,et al.  Molecular profiles of progesterone receptor loss in human breast tumors , 2009, Breast Cancer Research and Treatment.

[36]  R. Gelber,et al.  Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  P. Neven,et al.  Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Adrian V. Lee,et al.  Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  D. Larsimont,et al.  Progesterone receptor testing: not the right time to be buried. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  J. Itoh,et al.  Immunohistochemical Evaluation of Hormone Receptors in Breast Cancer: Which Scoring System Is Suitable for Highly Sensitive Procedures? , 2004, Applied immunohistochemistry & molecular morphology : AIMM.

[41]  K. Hirakawa,et al.  Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: Analysis for a cut-off point as the predictor for endocrine therapy , 2004, Breast cancer.

[42]  James D. Frost,et al.  Long-Term Outcome , 2003 .

[43]  E. Anderson.  Progesterone receptors – animal models and cell signaling in breast cancer: The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis , 2002, Breast Cancer Research.

[44]  H. Moch,et al.  Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.

[45]  A. Chott,et al.  Effect of formalin tissue fixation and processing on immunohistochemistry. , 2000, The American journal of surgical pathology.